12-deoxyphorbolphenylacetate

Subscribe to Selected New Research on 12-deoxyphorbolphenylacetate

3 relevant articles (0 outcomes, 0 trials/studies) found for this Bio-Agent

Description: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9aalpha))-isomer

Also Known As:

12-DOPP; 12-DOPPA; 12-DPPA; 12-deoxyphorbol-13-phenylacetate

Bio-Agent Context: Research Results

Organic Chemicals: 40

12-deoxyphorbolphenylacetate: 3

Related Diseases

1.	Neoplasms (Cancer) 02/01/1995 - "12-Deoxyphorbol-13-phenylacetate (dPP) is the prototype for a new class of phorbol derivatives that function as protein kinase C (PKC) activators with potent anti-tumor-promoting activity" 02/01/1995 - "Differential regulation by anti-tumor-promoting 12-deoxyphorbol-13-phenylacetate reveals distinct roles of the classical and novel protein kinase C isozymes in biological responses of primary mouse keratinocytes." Get all the results and reference details, order at left...
2.	Erythema 01/01/1981 - "Indomethacin was only partly successful as an antagonist since 10% inhibition of 12-DOPPA and no inhibition of 12-DOPPAA induced erythema was produced four hours after application" 01/01/1981 - "The pro-inflammatory tigliane esters 12-deoxyphorbolphenylacetate (12-DOPPA) and 12-deoxyphorbolphenylacetate-20-acetate (12-DOPPAA) at a dose of 0.1 microgram induced erythema in the mouse ear" 01/01/1981 - "Mepyramine and cyproheptadine also failed to inhibit the erythema, whereas hydrocortisone produced a 55% inhibition of the 12-DOPPA and a 20% inhibition of the 12-DOPPAA reaction" 01/01/1981 - "The membrane stabilising agents trifluoperazine, promethazine, imipramine and desmethylimipramine were the most successful compounds used in inhibiting both 12-DOPPA and 12-DOPPAA induced erythema" 01/01/1981 - "The free radical scavengers, phenol, thioanisole and sodium benzoate all produced less than 30% inhibition of 12-DOPPA induced erythema and less than 15% inhibition of 12-DOPPAA, whereas aminopyrine produced 70% and 25% inhibition of 12-DOPPA and 12-DOPPAA respectively" Get all the results and reference details, order at left...
3.	Dermatitis 09/28/2001 - "The last one showed activity on the ear oedema induced by 12-deoxyphorbol-13-phenylacetate (DPP), the dermatitis induced by multiple applications of 12-O-tetradecanoyl-13-acetate (TPA) and the paw oedemas induced by bradykinin and phospholipase A2" Get all the results and reference details, order at left...
3 Diseases and 3 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Phospholipases A2 (Phospholipase A2)
2.	Sodium Benzoate
3.	Phenol (Carbolic Acid)
4.	Free Radical Scavengers
5.	Trifluoperazine (Stelazine)
6.	Pyrilamine (Mepyramine)
7.	Protein Kinase C
8.	Promethazine (Promet)
9.	Isoenzymes
10.	Indomethacin (Indometacin)
20 Drugs and Important Bio-Agents and 3 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>